Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2016 · 10-Q
Revenue—
Net Income-$7.05M-$7.05MN/M vs Q2 2015 EPS Diluted-$5.26-$5.26N/M vs Q2 2015 Operating Income-$5,386,600N/M Operating Cash Flowderived-$1,506,200N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Sep 30, 2015 · filed Nov 16, 2015 · 47 d after period end